Research Article Details
| Article ID: | A48330 |
| PMID: | 16378280 |
| Source: | Turk J Gastroenterol |
| Title: | Obesity and related parameters of non-alcoholic steatohepatitis. |
| Abstract: | BACKGROUND/AIMS: The aim of this prospective study was to evaluate the clinical, biochemical and histopathological parameters of nonalcoholic steatohepatitis and the conditions associated with this disease. METHODS: Twenty-four patients were included in the study, each having been diagnosed with nonalcoholic steatohepatitis on the basis of liver biopsy and elimination of other possible causes of elevated aminotransferase levels. Measurements of degree of obesity, liver enzymes and serum lipids were recorded before liver biopsy and reevaluated after one or two months of a standard exercise and diet program. Serum insulin levels were also measured. Each liver biopsy was histologically examined for steatosis, inflammation, fibrosis, necrosis and iron storage, and semiquantitave assessment of these was recorded for three separate hepatic zones. RESULTS: The prevalence of obesity in the group was 79.2%, while the figure for overt and latent diabetes mellitus combined was 33.3%, and for hyperlipidemia was 83.3%. Compared to the rest of the group, the patients with severe steatosis had significantly higher serum lipid (particularly high triglyceride) and insulin levels (p<0.05 for both). There was a correlation between steatosis and obesity (p=0.06). More severe obesity, higher insulin and elevated aspartate aminotransferase were positively correlated with inflammation, whereas elevated serum triglyceride was negatively correlated with inflammation. There was a tendency towards normalization of liver enzyme levels after weight loss and dietary restrictions. CONCLUSIONS: Obesity and hyperlipidemia were associated with nonalcoholic steatohepatitis in the group studied. Obesity is not a factor in every case, but the study showed that restricted diet and exercise are significant forms of therapy for nonalcoholic steatohepatitis. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S08 | Lifestyle measures | Lifestyle intervention; weight loss; diet adaptation; dietary interventions; lifestyle modifications; Exercise | -- | -- | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |